



Aion Therapeutic Files Financials

TORONTO, ONTARIO – November 2, 2021 – Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (“**NP 12-203**”).

Management of the Company has been subject to a management cease trade order (the “**MCTO**”) in respect of the securities of the Company issued by the applicable securities regulators under NP 12-203 on August 31, 2021. The MCTO resulted from the delay in filing the Company’s annual financial statements and management discussion and analysis for the year ended April 30, 2021 (the “**Annual Disclosure Documents**”) by the prescribed deadline of August 31, 2021 and the subsequent delay in filing the Company’s interim financial statement and management discussion and analysis for the three-month period ended July 31, 2021 (the “**Interim Disclosure Documents**”) by the prescribed deadline of September 29, 2021.

The Company is pleased to announce that it has filed its Annual Disclosure Documents and Interim Disclosure Documents and these documents can be accessed under the Company’s profile at www.sedar.com.

About Aion Therapeutic Inc.

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.

For further information, please contact:

Public Relations

KCSA Strategic Communications

Anne Donohoe

aion@kcsa.com

Investor Relations

KCSA Strategic Communications

Phil Carlson

(212) 896-1233

aion@kcsa.com

Aion Therapeutic Inc.

Graham Simmonds

Executive Vice Chair & CEO

(416) 843-2881

DISCLAIMER & READER ADVISORY

Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.